Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AC Immune (ACIU) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for AC Immune (ACIU) over the last 12 years, with Q3 2025 value amounting to $34.7 million.

  • AC Immune's Cash & Equivalents fell 731.67% to $34.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $34.7 million, marking a year-over-year decrease of 731.67%. This contributed to the annual value of $41.4 million for FY2024, which is 5320.55% down from last year.
  • AC Immune's Cash & Equivalents amounted to $34.7 million in Q3 2025, which was down 731.67% from $31.1 million recorded in Q2 2025.
  • In the past 5 years, AC Immune's Cash & Equivalents ranged from a high of $89.2 million in Q4 2021 and a low of $101925.1 during Q3 2021
  • For the 5-year period, AC Immune's Cash & Equivalents averaged around $45.1 million, with its median value being $37.4 million (2024).
  • Per our database at Business Quant, AC Immune's Cash & Equivalents crashed by 9994.69% in 2021 and then skyrocketed by 7465024.22% in 2022.
  • Quarter analysis of 5 years shows AC Immune's Cash & Equivalents stood at $89.2 million in 2021, then crashed by 63.23% to $32.8 million in 2022, then surged by 169.9% to $88.5 million in 2023, then plummeted by 53.21% to $41.4 million in 2024, then dropped by 16.25% to $34.7 million in 2025.
  • Its last three reported values are $34.7 million in Q3 2025, $31.1 million for Q2 2025, and $22.2 million during Q1 2025.